MULTIPLE MYELOMA

<em>Targeted Oncology</em>&trade; will launch its third &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Monday, September 24.&nbsp;Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.

The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.

Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.

Treatment of Multiple Myeloma with High-Risk Cytogenetics

Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.&nbsp;

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;August 2018, including several new approvals, a priority review, breakthrough therapy designations, and more in a variety of cancer types.

Noopur Raje, MD, discusses&nbsp;the latest treatment advances in multiple myeloma, including the promising results&nbsp;seen with&nbsp;the anti-BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory disease.

FDA approval is being sought for a&nbsp;once-weekly dosing option of carfilzomib for use in combination with dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma.&nbsp;Amgen, the manufacturer of the proteasome inhibitor, announced the submission of a&nbsp;supplemental new drug application seeking this approval today.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the2nd Annual Live Medical Crossfire: Hematologic Malignancies meeting, Alexander M. Lesokhin, MD, assistant attending physician in the Department of Medicine and Myeloma Service at Memorial Sloan Kettering Cancer Center, discussed the current treatment landscape of multiple myeloma and where he predicts the field will be in the next decade. He also shared his thoughts on the current research in CAR T-cell therapy.

A supplemental biologics license application for elotuzumab<em>&nbsp;</em>has been granted a priority review by the FDA&nbsp;for use in combination with pomalidomide and low-dose dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.<br /> &nbsp;

Karyopharm Therapeutics has announced that a rolling submission of an FDA new drug application has been completed for&nbsp;selinexor as a treatment for patients with penta-refractory multiple myeloma,&nbsp;based on results from part 2 of the phase IIb STORM trial.

Treatment with chimeric antigen receptor B-cell maturation antigen T cells induced substantial antitumor activity in patients with heavily treated relapsed/refractory multiple myeloma, according to results from a first-in-human clinical trial.

Sagar Lonial, MD, professor and chair, Department of Hematology &amp; Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.